Martin Auster
Stock Analyst at UBS
(2.13)
# 2,809
Out of 4,761 analysts
47
Total ratings
51.61%
Success rate
4.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $68.25 | +75.82% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $42.59 | +146.54% | 7 | Mar 16, 2022 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $26 | $3.85 | +575.32% | 1 | Mar 22, 2021 | |
| SLDB Solid Biosciences | Maintains: Neutral | $105 → $120 | $5.78 | +1,976.12% | 4 | Mar 16, 2021 | |
| GLTO Galecto | Maintains: Outperform | $725 → $300 | $4.51 | +6,551.88% | 2 | Mar 16, 2021 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $49 → $58 | $8.33 | +596.28% | 3 | Mar 10, 2021 | |
| UTHR United Therapeutics | Maintains: Outperform | $169 → $196 | $361.10 | -45.72% | 4 | Feb 22, 2021 | |
| ALXO ALX Oncology Holdings | Maintains: Outperform | $62 → $98 | $1.12 | +8,650.00% | 2 | Feb 11, 2021 | |
| INSM Insmed | Maintains: Outperform | $50 → $60 | $81.06 | -25.98% | 2 | Jan 19, 2021 | |
| SRRK Scholar Rock Holding | Initiates: Outperform | $65 | $37.70 | +72.41% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $106.28 | -31.31% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $3.30 | - | 2 | Dec 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $12.84 | +507.48% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.82 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $8.25 | +421.21% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $34 | $31.12 | +9.25% | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $12.17 | +72.56% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $18.59 | -13.93% | 1 | May 7, 2020 |
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $68.25
Upside: +75.82%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $42.59
Upside: +146.54%
Fulcrum Therapeutics
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $3.85
Upside: +575.32%
Solid Biosciences
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $5.78
Upside: +1,976.12%
Galecto
Mar 16, 2021
Maintains: Outperform
Price Target: $725 → $300
Current: $4.51
Upside: +6,551.88%
Stoke Therapeutics
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $8.33
Upside: +596.28%
United Therapeutics
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $361.10
Upside: -45.72%
ALX Oncology Holdings
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $1.12
Upside: +8,650.00%
Insmed
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $81.06
Upside: -25.98%
Scholar Rock Holding
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $37.70
Upside: +72.41%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $106.28
Upside: -31.31%
Dec 10, 2020
Downgrades: Underperform
Price Target: n/a
Current: $3.30
Upside: -
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $12.84
Upside: +507.48%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $1.82
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $8.25
Upside: +421.21%
Jul 7, 2020
Initiates: Outperform
Price Target: $34
Current: $31.12
Upside: +9.25%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $12.17
Upside: +72.56%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $18.59
Upside: -13.93%